| Filed On | Filing |
|---|---|
| 10 Jun 2024 |
8-K/A: Departure/Election of Directors or Officers; Compensation
1. PURPOSE OF THE PLAN. The purpose of the 2024 Omnibus Incentive Plan (the “Plan”) is to provide favorable opportunities for directors, officers, employees, consultants or advisors employed by or providing services to Savara Inc., a Del... |
| 30 Oct 2013 |
8-K/A: Submission of Matters to a Vote of Security Holders
On June 19, 2013, the Company held its 2013 Annual Meeting of Stockholders (the “Annual Meeting”) and it reported the results of the Annual Meeting in the Original Current Report. One of the matters voted upon at the Annual Meeting was a... |
| 08 Mar 2012 |
8-K/A: Financial Statements and Exhibits
The accompanying unaudited pro forma condensed combined statement of operations presents the pro forma consolidated results of operations of the combined company for the year ended December 31, 2011 based upon the historical financial st... |
| 09 Nov 2011 |
8-K/A: Financial Statements and Exhibits
The accompanying unaudited pro forma condensed combined statement of operations present the pro forma consolidated results of operations of the combined company for the nine months ended September 30, 2011 based upon the historical, unau... |
| 25 Oct 2011 |
8-K/A: Financial Statements and Exhibits
Nature of operations: The corporation is a development-stage enterprise developing a purified form of a rheologic and antithrombotic agent, Poloxamer 188, or P188. During the period from January 12, 2004 (date of inception) through March... |
| 03 Jun 2011 |
8-K/A: Financial Statements and Exhibits
We have audited the accompanying balance sheets of SynthRx, Inc. (a development stage enterprise) as of December 31, 2010 and 2009, and the related statements of operations, stockholders’ deficit and cash flows for the years then ended a... |
| 06 Mar 2008 |
8-K/A: Departure/Election of Directors or Officers; Compensation
Explanatory Note: ADVENTRX Pharmaceuticals, Inc. (the "Company") is filing this Amendment No. 1 to supplement Item 5.02 of the Current Report on Form 8-K originally filed with the Securities and Exchange Commission on February 25, 2008 (... |
| 02 Oct 2006 | 8-K/A: Entry into a Material Definitive Agreement; Departure/Election of Directors or Officers; Compensation |
| 01 May 2006 |
8-K/A: Completion of Acquisition or Disposition of Assets
This Agreement and Plan of Merger (this “Agreement”) is made and entered into as of April 7, 2006 (the “Agreement Date”), by and among ADVENTRX Pharmaceuticals, Inc., a Delaware corporation (“Parent”), Speed Acquisition, Inc., a Delaware... |
| 27 Mar 2006 |
8-K/A: Non-Reliance on Previously Issued Financial Statements
We have read Item 4.02 included in Amendment No. 1 to the Form 8-K dated March 27, 2006 of Adventrx Pharmaceuticals, Inc. (Commission file No. 001-32157) filed with the Securities and Exchange Commission and are in agreement with the sta... |
| 23 Apr 2004 |
8-K/A: Changes in Control of Registrant; Completion of Acquisition or Disposition of Assets
BIOQUEST, Inc., a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware (the "Corporation"), does hereby certify as follows: |
| 13 Apr 2004 |
8-K/A: Other Events
This Common Stock and Warrant Purchase Agreement (this "AGREEMENT"), dated as of April 5, 2004 (the "AGREEMENT DATE"), is among ADVENTRX Pharmaceuticals, Inc., a Delaware corporation (the "COMPANY"), and each of the persons and entities ... |
Loading...